abivertinib

third generation inhibitor of the EGFR (epidermal growth factor receptor)

Also Known As:

2-propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-; 2-propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-, (2Z)-2-butenedioate (1:1); 2-propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-, (2Z)-2-butenedioate, hydrate (1:1:2); A-610MA; A610MA; AC-0010; AC-0010 maleate dihydrate; AC-0010MA; AC0010; AC0010MA; ACEA100610; EX-ACEA0010; EX-ACEA0010MA; EXACEA0010MA; Fujovee; N-(3-((2-((3-Fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)acrylamide; STI-5656; STI5656; abivertinib maleate; abivertinib maleate anhydrous; abivertinib maleate dihydrate; avitinib; avitinib maleate

Networked: 24 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hu, Pei: 6 articles (01/2022 - 11/2016)
2.	Zhang, Li: 6 articles (01/2022 - 11/2016)
3.	Jin, Jie: 5 articles (06/2022 - 04/2018)
4.	Xu, Xiao: 5 articles (01/2022 - 07/2015)
5.	Zheng, Xin: 5 articles (01/2022 - 05/2017)
6.	Huang, Xin: 4 articles (06/2022 - 10/2019)
7.	Li, Xia: 4 articles (06/2022 - 04/2018)
8.	Tang, Wei: 4 articles (01/2022 - 11/2016)
9.	Wang, Lu: 4 articles (01/2021 - 05/2017)
10.	Xu, Wanhong: 4 articles (01/2021 - 11/2016)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/2022 - "Previous studies have shown that abivertinib has promising antitumor activity and a well-tolerated safety profile in patients with non-small-cell lung cancer. " 01/01/2018 - "Non-small cell lung cancer (NSCLC) patients with the EGFR T790 M mutation were orally administered avitinib (150-300 mg) twice daily for cycles of 28 continuous days. " 01/01/2018 - "Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation." 07/15/2017 - "AC0010 is an irreversible, mutant-selective EGFR inhibitor that effectively inhibits EGFR active and T790M resistance mutations in non-small cell lung cancer (NSCLC). " 07/08/2015 - "Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clinical trials, and will provide a precision targeted therapy for non-small cell lung cancer patients. "
2.	Disease Progression 01/01/2022 - "To establish recommended phase II dose (RP2D) in phase I and evaluate safety and efficacy of abivertinib in patients with EGFR Thr790Met point mutation (T790M)-positive(+) non-small cell lung cancer (NSCLC) with disease progression from prior EGFR inhibitors in phase II. This multicenter, open-label study included 367 adult Chinese patients. "
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/01/2019 - "Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia." 10/01/2020 - "Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner."
4.	Leukemia 10/01/2019 - "Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia." 10/01/2020 - "Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner."
5.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/01/2018 - "Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma."

Related Drugs and Biologics

1.	Homoharringtonine
2.	Tyrosine Kinase Inhibitors
3.	abivertinib
4.	EKB 569
5.	olmutinib
6.	ErbB Receptors (EGF Receptor)
7.	Apigenin
8.	Growth Factor Receptors
9.	Cytokines
10.	Interleukin-6 (Interleukin 6)

Related Therapies and Procedures

1.	Therapeutics
2.	Microelectrodes
3.	Electrodes (Electrode)
4.	Oral Administration